Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

Abstract:
Targeted Synthetic Vaccine Particles (tSVP) Offer Potential for Increased Anti-Nicotine Efficacy to Increase Success of Smoking Cessation

Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

Watertown, MA | Posted on August 16th, 2010

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH). The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

The $3 million grant will support the funding of a clinical drug candidate from Selecta's pipeline, and assist with advancing a nicotine vaccine from preclinical through early clinical evaluation. The award is one of a select number of grants provided nationwide by NIH under the unique BRDG-SPAN program (Biomedical Research and Development and Growth To Spur the Acceleration of New Technologies Pilot Program) which is designed to bridge the gap between R&D and commercialization for promising new medical technologies.

"We are delighted that NIDA has recognized the uniqueness and potential advantages of Selecta's synthetic therapeutic vaccines and has elected to support Selecta's tSVP nicotine vaccine, in a very competitive process, to address the enormous unmet medical need of smoking cessation," said Werner Cautreels, Ph.D., Chief Executive Officer of Selecta Biosciences. "We view a nicotine vaccine as one of our promising programs that are poised to advance into human clinical trials based on our progress with Selecta's technology platform"

Selecta's tSVP technology offers in this case a new approach to a nicotine vaccine designed to boost immune responses, or more specifically nicotine antibody titers, beyond previous technologies. Selecta's tSVP immunomodulatory nanoparticles aim to induce highly predictable immune responses, for durable effect in smoking cessation. Although previous research has shown the therapeutic potential for vaccinating against nicotine by inducing nicotine-specific antibodies, published studies with differently designed vaccines show that only a small fraction of study patients achieved anti-nicotine titers sufficient to increase smoking cessation above placebo.

####

About Selecta Biosciences
Selecta Biosciences, Inc. is a biopharmaceutical company developing first-in-class synthetic nanoparticle vaccines and immunotherapies, with the first applications focused on nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. The tSVP platform enables full-integration of the key vaccine components, antigens and adjuvants, for highly-effective targeting to immune cells to produce an optimal immune response. The tSVP vaccines mimic the structure of natural pathogens with regards to size, shape and the sequence of immunological information that it delivers specifically to immune cells, thus harnessing the body's defense system to produce a robust immune response. The unique attributes of full-integration, targeting and natural structure conferred by the tSVP platform create synthetic nanoparticle vaccines that are engineered for unprecedented safety and efficacy. This novel approach enables expanded opportunities for tSVP vaccines, and the company is pursuing opportunities across a range of high unmet medical need applications, including infectious, metabolic, CNS and inflammatory diseases.

Selecta was founded in 2008 by three academic pioneers in the fields of nanotechnology and immunology: Professor Robert Langer (MIT), and Professors Omid Farokhzad and Ulrich von Andrian (Harvard Medical School). Selecta is backed by leading venture investors including, Polaris Venture Partners, Flagship Ventures, NanoDimension, OrbiMed Advisors and Leukon Investments. For more information please visit the company website at www.selectabio.com.

About Smoking Cessation
Through the use of tobacco, nicotine is one of the most heavily used addictive drugs and smoking is the leading preventable cause of disease, disability, and death in the United States. According to the CDC there are approximately 438,000 premature deaths in the U.S. per year due to smoking and approximately 38,000 lung cancer and heart disease deaths annually were attributable to exposure to secondhand smoke. Additionally, smoking costs the U.S. $97 billion dollars a year in direct healthcare costs and an additional $92 billion a year in productivity losses.

For more information, please click here

Contacts:
Gina Nugent
The Yates Network
Tel: 617-460-3579

Copyright © Selecta Biosciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A Stretchy Mesh Heater for Sore Muscles July 6th, 2015

BBC World Service to broadcast Forum discussion on graphene July 6th, 2015

Production of Zirconium Carbide Nanoparticles at Low Temperature without Thermal Operations July 5th, 2015

A 'movie' of ultrafast rotating molecules at a hundred billion per second: A quantum wave-like nature was successfully observed in rotating nitrogen molecules July 4th, 2015

Nanomedicine

A Stretchy Mesh Heater for Sore Muscles July 6th, 2015

New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015

Groundbreaking research to help control liquids at micro and nano scales July 3rd, 2015

Iranian Scientists Find Simple, Economic Method to Synthesize Antibacterial Nanoparticles July 2nd, 2015

Announcements

A Stretchy Mesh Heater for Sore Muscles July 6th, 2015

BBC World Service to broadcast Forum discussion on graphene July 6th, 2015

Production of Zirconium Carbide Nanoparticles at Low Temperature without Thermal Operations July 5th, 2015

A 'movie' of ultrafast rotating molecules at a hundred billion per second: A quantum wave-like nature was successfully observed in rotating nitrogen molecules July 4th, 2015

Personal Care

Mesoporous Particles for the Development of Drug Delivery System Safe to Human Bodies June 9th, 2015

Nanoparticles in consumer products can significantly alter normal gut microbiome May 4th, 2015

Application of Egg White in Production of Nanoparticles April 6th, 2015

Sunblock poses potential hazard to sea life August 20th, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Pioneering Southampton scientist awarded prestigious physics medal July 3rd, 2015

Discovery of nanotubes offers new clues about cell-to-cell communication July 2nd, 2015

World’s 1st Full-Color, Flexible, Skin-Like Display Developed at UCF June 24th, 2015

Physicists fine-tune control of agile exotic materials: Tunable hybrid polaritons realized with graphene layer on hexagonal boron nitride June 24th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project